| Avalon GloboCare is a holding company. Through its subsidiaries, Co. is a clinical-stage CellTech bio-developer focused on advancing and empowering transformative immune effector cell therapy, exosome technology, as well as Coronavirus Disease 2019 (COVID-19) related diagnostics and therapeutics. Co. also provides advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as engage in healthcare and CellTech industry markets. Co. is engaging in the fields of cellular immunotherapy (including chimeric antigen receptor-T/NK), exosome technology (Avalon Clinical-grade Tissue-specific Exosome), and COVID-19 related vaccine and therapeutics. The AVCO average annual return since 2018 is shown above.
The Average Annual Return on the AVCO average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AVCO average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AVCO average annual return calculation with any dividends reinvested as applicable (on ex-dates).